India Plans Price Controls on Patented Drugs - WSJ.com - 0 views
-
India plans to widen the scope of price controls on pharmaceuticals
-
The new proposals would extend price restrictions beyond generic medicines to apply for the first time to patented drugs
-
The plans come as Bayer AG BAYN.XE -0.17% Bayer AG Germany: Xetra €94.89 -0.16 -0.17% Nov. 15, 2013 5:35 pm Volume : 2.67M P/E Ratio 25.24 Market Cap €78.47 Billion Dividend Yield 2.00% Rev. per Employee €363,176 10/31/13 Bayer Boosted by New Drugs 09/13/13 Bayer Under Scrutiny in China More quote details and news » BAYN.XE in Your Value Your Change Short position is fighting an order from India's patent authority that required the Germany company to issue a license allowing an Indian generic-drug company to sell a less expensive copy of Bayer's patented cancer drug Nexavar.
- ...3 more annotations...